D&A at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's D&A?
- Regeneron Pharmaceuticals (REGN) reported D&A of $123.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's D&A changed year-over-year?
- Regeneron Pharmaceuticals's D&A decreased by 2.9% year-over-year, from $126.9M to $123.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's D&A has grown at a 17.4% compound annual growth rate (CAGR), from $286.2M to $543.7M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.